Bravecto Plus


fluralaner / moxidectin

This medicine is authorised for use in the European Union.


Bravecto Plus is a veterinary medicine used in cats to treat mixed infestations with both ticks or fleas and ear mites and/or worms that live inside the body. The medicine can be used:

  • to treat tick infestations
  • to treat flea infestations. It can also be used as part of a treatment for flea allergy dermatitis (an allergic reaction to flea bites)
  • to treat ear mite infestations
  • to treat roundworms and hookworms in the gut
  • to prevent heartworm disease

Bravecto Plus must only be used when there is a need to treat ticks or fleas and one or more of the parasites listed above. Bravecto Plus contains the active substances fluralaner and moxidectin.

This EPAR was last updated on 11/02/2021

Authorisation details

Product details
Bravecto Plus
Agency product number
Active substance
  • fluralaner
  • moxidectin
International non-proprietary name (INN) or common name
  • fluralaner
  • moxidectin
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

04/02/2021 Bravecto Plus - EMEA/V/C/004440 - IG/1331


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Antiparasitic products, insecticides and repellents

  • Endectocides

  • Milbemycins

Therapeutic indication

For cats with, or at risk from, mixed parasitic infestations by ticks or fleas and ear mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and one or more of the other target parasites is indicated at the same time.

For the treatment of tick and flea infestations in cats providing immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

For the treatment of infestations with ear mites (Otodectes cynotis).

For the treatment of infections with intestinal roundworm (4th stage larvae, immature adults and adults of Toxocara cati) and hookworm (4th stage larvae, immature adults and adults of Ancylostoma tubaeforme).

When administered repeatedly at a 12-week interval, the product continuously prevents heartworm disease caused by Dirofilaria immitis

Assessment history

How useful was this page?

Add your rating